Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery

References

• De Backer L, Cerrada A, Pérez-Gil J, et al. Bio-inspired materials in drug delivery: exploring the role of pulmonary surfactant in siRNA inhalation therapy. J Control Release. 2015;220(Pt B):642–650.
   PubMedGoogle Scholar
• Patil TS, Deshpande AS, Deshpande S, et al. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. J Drug Target. 2019;27(1):12–27.
   PubMed Web of Science ®Google Scholar
• Ruge CA, Kirch J, Lehr C-M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–413.
   PubMed Web of Science ®Google Scholar
• Katare YK, Piazza JE, Bhandari J, et al. Intranasal delivery of antipsychotic drugs. Schizophr Res. 2017;184:2–13.
   PubMed Web of Science ®Google Scholar
• Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15(4):5852–5873.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang Q. Nanoparticle systems for nose-to-brain delivery. Brain targeted drug delivery system. Amsterdam: Elsevier; 2019. p. 219–239.
   Google Scholar
• Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;11(3):113.
   PubMed Web of Science ®Google Scholar
• Medhi R, Srinoi P, Ngo N, et al. Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater. 2020;3(9):8557–8580.
   Web of Science ®Google Scholar
• Chan SK, Du P, Ignacio C, et al. Biomimetic virus-like particles as severe acute respiratory syndrome coronavirus 2 diagnostic tools. ACS Nano. 2021;15(1):1259–1272.
   PubMed Web of Science ®Google Scholar
• Witika BA, Makoni PA, Mweetwa LL, et al. Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment. Molecules. 2020;25(24):5952.
   PubMed Web of Science ®Google Scholar
• Mariano G, Farthing RJ, Lale-Farjat SL, et al. Structural characterization of SARS-CoV-2: where we are, and where we need to be. Front Mol Biosci. 2020;7:605236.
   PubMed Web of Science ®Google Scholar
• Brenner JS, Kiseleva RY, Glassman PM, et al. The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulm Circ. 2018;8(1):2045893217752329.
   Web of Science ®Google Scholar
• Lindsley WG, Pearce TA, Hudnall JB, et al. Quantity and size distribution of cough-generated aerosol particles produced by influenza patients during and after illness. J Occup Environ Hyg. 2012;9(7):443–449.
   PubMed Web of Science ®Google Scholar
• Madas BG, Füri P, Farkas Á, et al. Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airways upon exposure to cough-generated droplets and aerosol particles. Sci Rep. 2020;10(1):22430–22438.
   PubMed Web of Science ®Google Scholar
• Muralidharan P, Malapit M, Mallory E, et al. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine. 2015;11(5):1189–1199.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646.
   PubMed Web of Science ®Google Scholar
• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15(2):434–455.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Leung SSY, Tang P, et al. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev. 2015;85:83–99.
   PubMed Web of Science ®Google Scholar
• Klein DM, Poortinga A, Verhoeven FM, et al. Degradation of lipid based drug delivery formulations during nebulization. Chem Phys. 2021;547:111192.
   Web of Science ®Google Scholar
• Iwanaga T, Tohda Y, Nakamura S, et al. The Respimat® soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. 2019;39(11):1021–1030.
   PubMed Web of Science ®Google Scholar
• Wang Z, Cuddigan JL, Gupta SK, et al. Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension. Int J Pharm. 2016;512(1):305–313.
   PubMed Web of Science ®Google Scholar
• Mejías JC, Roy K. In-vitro and in-vivo characterization of a multi-stage enzyme-responsive nanoparticle-in-microgel pulmonary drug delivery system. J Controlled Release. 2019;316:393–403.
   PubMed Web of Science ®Google Scholar
• Keil TW, Feldmann DP, Costabile G, et al. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur J Pharm Biopharm. 2019;143:61–69.
   PubMed Web of Science ®Google Scholar
• Hu Q, Bai X, Hu G, et al. Unveiling the molecular structure of pulmonary surfactant corona on nanoparticles. ACS Nano. 2017;11(7):6832–6842.
   PubMed Web of Science ®Google Scholar
• Xu Y, Deng L, Ren H, et al. Transport of nanoparticles across pulmonary surfactant monolayer: a molecular dynamics study. Phys Chem Chem Phys. 2017;19(27):17568–17576.
   PubMed Web of Science ®Google Scholar
• Li J, Ma X, Guo S, et al. A hydrophobic-interaction-based mechanism triggers docking between the SARS-CoV-2 spike and angiotensin-converting enzyme 2. Glob Chall. 2020;4(12):2000067.
   PubMedGoogle Scholar
• Chen P, Zhang Z, Xing J, et al. Physicochemical properties of nanoparticles affect translocation across pulmonary surfactant monolayer. Mol Phys. 2017;115(24):3143–3154.
   Web of Science ®Google Scholar
• Liu Q, Guan J, Qin L, et al. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discov Today. 2020;25(1):150–159.
   PubMed Web of Science ®Google Scholar
• Swiss Institute of Bioinformatics. ExPASy (Bioinformatics Resource Tool): ProtParam Tool; [cited 2021 Aug 18]. Available from:https://web.expasy.org/protparam/.
   Google Scholar
• Scheller C, Krebs F, Minkner R, et al. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control. Electrophoresis. 2020;41(13–14):1137–1151.
   PubMed Web of Science ®Google Scholar
• Meng Q, Sun Y, Cong H, et al. An overview of chitosan and its application in infectious diseases. Drug Deliv Transl Res. 2021:11(1340–1351):1–12.
   PubMed Web of Science ®Google Scholar
• Ni R, Zhao J, Liu Q, et al. Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery. Eur J Pharm Sci. 2017;99:137–146.
   PubMed Web of Science ®Google Scholar
• Motiei M, Kashanian S, Lucia LA, et al. Intrinsic parameters for the synthesis and tuned properties of amphiphilic chitosan drug delivery nanocarriers. J Control Release. 2017;260:213–225.
   PubMed Web of Science ®Google Scholar
• Chen D, Liu J, Wu J, et al. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Deliv. 2021;18(5):595–606.
   PubMed Web of Science ®Google Scholar
• Brooks AE. The potential of silk and silk-like proteins as natural mucoadhesive biopolymers for controlled drug delivery. Front Chem. 2015;3:65.
   PubMed Web of Science ®Google Scholar
• Pawłowski PH. Charged amino acids may promote coronavirus SARS-CoV-2 fusion with the host cell. AIMS Biophysics. 2021;8(1):111–120.
   Web of Science ®Google Scholar
• da Silva LCN, Mendonça JSP, de Oliveira WF, et al. Exploring lectin-glycan interactions to combat COVID-19: lessons acquired from other enveloped viruses. Glycobiology. 2021;31(4):358–371.
   PubMed Web of Science ®Google Scholar
• Mehnath S, Sithika MAA, Arjama M, et al. Sericin-chitosan doped maleate gellan gum nanocomposites for effective cell damage in Mycobacterium tuberculosis. Int J Biol Macromol. 2019;122:174–184.
   PubMed Web of Science ®Google Scholar
• Chen S, Hanning S, Falconer J, et al. Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019;144:18–39.
   PubMed Web of Science ®Google Scholar
• Siddiquie RY, Agrawal A, Joshi SS. Surface alterations to impart antiviral properties to combat COVID-19 transmission. Trans Indian Natl Acad Eng. 2020;5(2):343–347.
   Google Scholar
• Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742.
   PubMed Web of Science ®Google Scholar
• Mehta M, Tewari D, Gupta G, et al. Oligonucleotide therapy: an emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chem-Biol Interact. 2019;308:206–215.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Man RC, Liao Q, et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102–115.
   PubMed Web of Science ®Google Scholar
• Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16(1):22–69.
   PubMedGoogle Scholar
• Joshi N, Shirsath N, Singh A, et al. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep. 2014;4:7085.
   PubMed Web of Science ®Google Scholar
• Silva AS, Sousa AM, Cabral RP, et al. Aerosolizable gold nano-in-micro dry powder formulations for theragnosis and lung delivery. Int J Pharm. 2017;519(1–2):240–249.
   PubMedGoogle Scholar
• Mirastschijski U, Dembinski R, Maedler K. Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia. Front Med. 2020;7:254.
   PubMed Web of Science ®Google Scholar
• Borodina T, Trushina D, Marchenko I, et al. Calcium carbonate-based mucoadhesive microcontainers for intranasal delivery of drugs bypassing the blood–brain barrier. BioNanoSci. 2016;6(3):261–268.
   Web of Science ®Google Scholar
• Triolo D, Craparo E, Porsio B, et al. Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate. Colloids Surf B Biointerfaces. 2017;151:206–214.
   PubMed Web of Science ®Google Scholar
• Porsio B, Craparo EF, Mauro N, et al. Mucus and Cell-Penetrating nanoparticles embedded in nano-into-Micro formulations for pulmonary delivery of ivacaftor in patients with cystic fibrosis. ACS Appl Mater Interfaces. 2018;10(1):165–181.
   PubMed Web of Science ®Google Scholar
• Porsio B, Cusimano MG, Schillaci D, et al. Nano into micro formulations of tobramycin for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Biomacromolecules. 2017;18(12):3924–3935.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lapierre J, Ojha CR, et al. Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep. 2017;7(1):1862.
   PubMed Web of Science ®Google Scholar
• Price DN, Stromberg LR, Kunda NK, et al. In vivo pulmonary delivery and magnetic-targeting of dry powder nano-in-microparticles. Mol Pharm. 2017;14(12):4741–4750.
   PubMedGoogle Scholar
• Zhong Q, Humia BV, Punjabi AR, et al. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers. Eur J Pharm Sci. 2017;109:86–95.
   PubMed Web of Science ®Google Scholar
• Zhu X, Kong Y, Liu Q, et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Pulm Pharmacol Ther. 2019;55:50–61.
   PubMed Web of Science ®Google Scholar
• Khan I, Apostolou M, Bnyan R, et al. Paclitaxel-loaded micro or nano transfersome formulation into novel tablets for pulmonary drug delivery via nebulization. Int J Pharm. 2020;575:118919.
   PubMedGoogle Scholar
• Abdelrady H, Hathout RM, Osman R, et al. Exploiting gelatin nanocarriers in the pulmonary delivery of methotrexate for lung cancer therapy. Eur J Pharm Sci. 2019;133:115–126.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang Y, Guo Z, et al. Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J Control Release. 2019;295:153–163.
   PubMed Web of Science ®Google Scholar
• Türeli NG, Torge A, Juntke J, et al. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur J Pharm Biopharm. 2017;117:363–371.
   PubMed Web of Science ®Google Scholar
• Scolari IR, Páez PL, Sánchez-Borzone ME, et al. Promising Chitosan-Coated Alginate-Tween 80 nanoparticles as rifampicin coadministered ascorbic acid delivery carrier against Mycobacterium tuberculosis. AAPS PharmSciTech. 2019;20(2):67.
   PubMed Web of Science ®Google Scholar
• Preis E, Baghdan E, Agel MR, et al. Spray dried curcumin loaded nanoparticles for antimicrobial photodynamic therapy. Eur J Pharm Biopharm. 2019;142:531–539.
   PubMed Web of Science ®Google Scholar
• Nichols CE, Shepherd DL, Hathaway QA, et al. Reactive oxygen species damage drives cardiac and mitochondrial dysfunction following acute nano-titanium dioxide inhalation exposure. Nanotoxicology. 2018;12(1):32–48.
   PubMed Web of Science ®Google Scholar
• Zhang F, Aquino GV, Dabi A, et al. Assessing the translocation of silver nanoparticles using an in vitro co-culture model of human airway barrier. Toxicol In Vitro. 2019;56:1–9.
   PubMed Web of Science ®Google Scholar
• Wu T, Zhang S, Liang X, et al. The apoptosis induced by silica nanoparticle through endoplasmic reticulum stress response in human pulmonary alveolar epithelial cells. Toxicol In Vitro. 2019;56:126–132.
   PubMed Web of Science ®Google Scholar
• Haque S, Whittaker M, McIntosh MP, et al. A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. Eur J Pharm Biopharm. 2018;125:1–12.
   PubMed Web of Science ®Google Scholar
• Costamagna F, Hillaireau H, Vergnaud J, et al. Nanotoxicology at the particle/micelle frontier: influence of core-polymerization on the intracellular distribution, cytotoxicity and genotoxicity of polydiacetylene micelles. Nanoscale. 2020;12(4):2452–2463.
   PubMed Web of Science ®Google Scholar
• Mendonça MCP, Radaic A, Garcia-Fossa F, et al. The in vivo toxicological profile of cationic solid lipid nanoparticles. Drug Deliv and Transl Res. 2020;10(1):34–42.
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, et al. Dendrimer toxicity: let’s meet the challenge. Int J Pharm. 2010;394(1–2):122–142.
   PubMed Web of Science ®Google Scholar
• Tagit O, De Ruiter M, Brasch M, et al. Quantum dot encapsulation in virus-like particles with tuneable structural properties and low toxicity. RSC Adv. 2017;7(60):38110–38118.
   Web of Science ®Google Scholar
• Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.
   PubMed Web of Science ®Google Scholar
• Ho W, Gao M, Li F, et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv Healthc Mater. 2021;10(8):e2001812.
   PubMed Web of Science ®Google Scholar
• Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021;24(3):368–378.
   PubMed Web of Science ®Google Scholar
• Petruk G, Puthia M, Petrlova J, et al. SARS-CoV-2 Spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. bioRxiv. 2020.
   Google Scholar